Amylyx Pharmaceuticals 与相关方签署的多肽协议，在定价策略上选择了固定量定价模式，同时配套了年度调整机制。这一安排已在提交给美国证券交易委员会（SEC）的文件中详细披露。简而言之，双方约定的价格并非一成不变，而是以固定量为基准，每年动态审视并可能进行调整。这一细节，源自公司最新提交的监管申报材料。
Amylyx Pharmaceuticals 与相关方签署的多肽协议，在定价策略上选择了固定量定价模式，同时配套了年度调整机制。这一安排已在提交给美国证券交易委员会（SEC）的文件中详细披露。简而言之，双方约定的价格并非一成不变，而是以固定量为基准，每年动态审视并可能进行调整。这一细节，源自公司最新提交的监管申报材料。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.